
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 11, 2013

CymaBay Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-55021
(Commission
File Number)

94-3103561
(IRS Employer
Identification No.)

3876 Bay Center Place
Hayward, CA 94545
(Address of principal executive offices)

(510) 293-8800
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01. Other Events

On December 11, 2013, CymaBay Therapeutics, Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated December 11, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CymaBay Therapeutics, Inc.

By: /s/ Charles McWherter

Name: Charles McWherter

Title: Chief Scientific Officer

Dated: December 11, 2013

**CymaBay Therapeutics**

3876 Bay Center Place
Hayward, CA 94545
www.cymabay.com
510-293-8800 office
510-293-9090 fax

CYMABAY THERAPEUTICS, INC. COMPLETES FINANCING***CymaBay completes \$38 million financing***

Hayward, CA (December 11, 2013): On November 22, 2013, CymaBay Therapeutics, Inc. completed a private placement of common stock and warrants to purchase common stock with aggregate gross proceeds of \$33.2 million. CymaBay issued an aggregate of 6,031,028 shares of common stock and warrants exercisable for 1,206,198 shares of common stock to investors in closings on September 30, 2013 and October 31, 2013. Furthermore, CymaBay entered into an arrangement with investors to purchase 604,000 shares of its common stock and 120,800 warrants to purchase shares of common stock as part of the financing, the sale of which will occur shortly after CymaBay lists its common stock on the over-the-counter market. In addition, CymaBay raised an additional \$5.0 million in venture debt from Oxford Finance and Silicon Valley Bank in connection with the financing. The proceeds from the financing will be used to further support the Phase 2b clinical development of CymaBay's lead investigational product, arhalofenate.

The securities issued in the financing have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

For additional information about CymaBay visit www.cymabay.com.

Contact:

Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
sshah@cymabay.com

or

Adam Cutler
The Trout Group, LLC
(646) 378-2936
CymaBay@troutgroup.com